FDA “Follow-On” Biologics Framework Development Will Become More Public
Executive Summary
FDA's development of a framework for "follow-on" biologics will become a more public process after the agency resolves internal questions about scientific issues, Office of New Drugs Deputy Director Sandra Kweder, MD, said April 16
You may also be interested in...
“Follow-On” Biologics Guidance Will Limit Use Of Data To “Public Domain”
FDA's upcoming draft guidance on follow-on biologics will allow use of data that are in the public domain only, Center for Drug Evaluation & Research acting Director Steven Galson, MD, told the Schwab Soundview Washington Research Group health care conference May 5
“Follow-On” Biologics Guidance Will Limit Use Of Data To “Public Domain”
FDA's upcoming draft guidance on follow-on biologics will allow use of data that are in the public domain only, Center for Drug Evaluation & Research acting Director Steven Galson, MD, told the Schwab Soundview Washington Research Group health care conference May 5
FDA Generic Biologics “Structure” To Come Soon; Policy Debate In 2005
FDA hopes to be in a position to kick off a legislative and policy debate on the feasibility of "follow-on" biologics by the beginning of 2005